View source for MEND-CABG II trial does not suggest improved outcomes with the novel drug MC1 in patients undergoing high risk coronary artery bypass surgery
Jump to navigation
Jump to search
You do not have permission to edit this page, for the following reason:
You can view and copy the source of this page.
Pages included on this page: